282 results on '"Rowett, Debra"'
Search Results
252. Lipid lowering therapy for adults with diabetes
- Author
-
Jackowski, Leslie, Crockett, Josephine, and Rowett, Debra
- Subjects
lipid lowering ,Pharmaceutical Sciences ,diabetes ,Clinical Pharmacy and Pharmacy Practice ,Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Refereed/Peer-reviewed
- Published
- 2008
253. Improving the quality, effectiveness and sustainability of smoking cessation services delivered through community pharmacies
- Author
-
Brisbane 2004-07-28, Gilbert, Andrew Leigh, Kardachi, Grant, Rowett, Debra, Vial, Robyn, and Edwards,David Alexander
- Subjects
pharmacies ,smoking cessation services - Published
- 2004
254. Clinical networks influencing policy and practice: the establishment of advanced practice pharmacist roles for specialist palliative care services in South Australia
- Author
-
Debra Rowett, Kate Swetenham, David Stephenson, Swetenham, Kate, Rowett, Debra, and Stephenson, David
- Subjects
pharmacy ,palliative therapy ,Palliative care ,Pharmacist ,Pharmacy ,Community Pharmacy Services ,Population health ,community care ,Community Networks ,Professional Role ,Nursing ,Health care ,organization and management ,Humans ,Medicine ,Cooperative Behavior ,Policy Making ,health care economics and organizations ,business.industry ,Health Policy ,Palliative Care ,health care policy ,Workforce ,Pharmacy practice ,business ,Quality use of medicines - Abstract
Objectives: To operationalise the concept of 'advanced practice roles' in pharmacy within the new integrated regionalised palliative care service model outlined in the Palliative Care Services Plan 2009-2016, SA Health. Methods: A working group was established under the auspices of the Palliative Care Clinical Network to progress the development of advanced practice pharmacist roles for regionalised palliative care services. A pharmacy stakeholder forum was conducted in December 2010 to provide further guidance on the advanced practice pharmacist roles in the following domains: education; network links and partnerships; quality and safety; and research. Results: Advanced practice pharmacist positions were created for each of the three regionalised palliative care services in South Australia (SA). Funding was obtained for a Statewide Palliative Care Pharmacy Network project, to build a sustainable community-based palliative care pharmacy network. Advanced practice pharmacists commenced in the regionalised palliative care services of SA on 4 October 2011. Conclusions: The Statewide Palliative Care Clinical Network and the SA Palliative Care Plan provided a policy framework that supported involvement and advocacy in the planning of the advanced practice pharmacist roles. Collaboration between leaders in workforce reform, service planners, specialist palliative care providers and the pharmacy sector was a key enabler for developing the advanced practice pharmacist positions for regionalised palliative care services. What is known about the topic? The advanced practice palliative care pharmacist role reflects a new direction for the discipline of pharmacy and has been embraced at a time when a nationally endorsed Advanced Pharmacy Practice Framework has been published, while recognising that registration for pharmacists in Australia currently does not have specific endorsement for advanced practice. What does this paper add? This paper outlines the value of collaboration across settings and sectors. There is an opportunity for these roles to align with the new nationally endorsed framework for advanced practice in pharmacy. What are the implications for practitioners? These new positions strengthen the links between the hospital and community pharmacy sectors to enhance a quality use of medicines approach with improved access to end-of-life medicines for home-based palliative care clients, which actively facilitates a home death for those who choose it. Refereed/Peer-reviewed
- Published
- 2014
255. The effect of hypoxaemia on drug disposition in chronic respiratory failure
- Author
-
D. Rowett, K. Latimer, L. N. Sansom, R. E. Ruffin, F. May, G. Henderson, P. J. Hayball, Received: February 1995/Accepted May, Rowett, Debra, Latimer, K, Ruffin, Richard E, May, Frank, and Henderson, G
- Subjects
Adult ,Male ,Biological Availability ,Hypoxemia ,Oxygen Consumption ,Furosemide ,medicine ,Humans ,Hypoglycemic Agents ,Pharmacology (medical) ,Hypoxia ,Acetaminophen ,Aged ,Pharmacology ,Cross-Over Studies ,business.industry ,Respiratory disease ,General Medicine ,Disposition ,respiratory system ,Hypoxia (medical) ,Analgesics, Non-Narcotic ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Respiratory failure ,Pharmacodynamics ,Anesthesia ,Chronic Disease ,Female ,medicine.symptom ,business ,Respiratory Insufficiency ,medicine.drug ,Protein Binding - Abstract
The influence of hypoxaemia on the disposition of two common drugs has been examined in ten adults with stable chronic respiratory failure.There were two experimental periods in this cross-over study: during these periods supplemental oxygen was either withheld or administered to impose clinical hypoxaemia or maintain normoxaemia, respectively. Each participant received either oral (40 mg) or intravenous (20 mg) frusemide combined with oral paracetamol (500 mg) on consecutive days of the two experimental periods.The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2or = 60 Torr) [76.9 and 62.4 ml.min-1]. The volume of distribution was not affected by acute hypoxaemia (121 ml.kg-1 without and 109 ml.kg-1 with oxygen; P0.05). Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1). The absolute bioavailability of frusemide during hypoxaemia (0.62) was not different to that obtained during normoxaemia (0.56). The combined sodium and potassium excretion rate (expressed as a function of the frusemide excretion rate) was not altered by changing the oxygen tension. The pharmacokinetics of paracetamol were unaffected by hypoxaemia.
- Published
- 1996
256. Community pharmacists: A forgotten resource for palliative care
- Author
-
Paul Hakendorf, Bel Morris, John Gray, David C. Currow, Paul A Tait, Debra Rowett, Tait, Paul Anthony, Gray, John, Hakendorf, Paul, Morris, Bel, Currow, David Christopher, and Rowett, Debra S
- Subjects
medicine.medical_specialty ,Prescription Drugs ,Palliative care ,Medicine (miscellaneous) ,Pharmacy ,Community Pharmacy Services ,prescription drug ,Health Services Accessibility ,Cohort Studies ,terminal care ,narcotic analgesic agent ,medicine ,Humans ,Cooperative Behavior ,Hospital pharmacy ,Medicine use ,Socioeconomic status ,Terminal Care ,Home environment ,Oncology (nursing) ,business.industry ,Palliative Care ,General Medicine ,Health Surveys ,Metropolitan area ,community pharmacy services ,Analgesics, Opioid ,Medical–Surgical Nursing ,England ,Family medicine ,Health Resources ,Interdisciplinary Communication ,Observational study ,business - Abstract
Timely access to medicines within the community is important for palliative patients where their preferred place of care is the home environment. The objective of this observational study is to establish baseline data to quantify the issue of poor access to medicines for symptom control in the last few days of life. The list of 13 medicines was generated from medicine use within a metropolitan palliative care unit. A survey was designed to determine which of these 13 medicines community pharmacies stock, the expiry date of this stock, awareness of palliative care patients by community pharmacists and basic demographic characteristics of the community pharmacies. Surveys were distributed, by post, to all community pharmacies in South Australia. The response rate was 23.7%, and was representative of all socioeconomic areas. Each pharmacy stocked a median of 3 medicines (range 0-12) with 1 in 8 pharmacies having none of the 13 medicines listed in the survey. When the data was combined to identify the range of medicines from all pharmacies within a geographical postcode region, the median number of medicines increased to 5 medicines per postcode. Just over 1 in 5 pharmacies reported learning about the palliative status of a patient through another health practitioner. Community pharmacies remain an underused resource to support timely access to medicines for community-based palliative patients. Palliative care services and government agencies can develop new strategies for better access to medicines that will benefit community patients and their carers. Refereed/Peer-reviewed
257. Pharmacovigilance in palliative care
- Author
-
David C. Currow, Debra Rowett, Rowett, Debra, and Currow, David
- Subjects
Drug ,medicine.medical_specialty ,Palliative care ,business.industry ,media_common.quotation_subject ,food and beverages ,opioids ,Good control ,Harm ,Pharmacovigilance ,Emergency medicine ,medicine ,adverse effects ,Pharmacology (medical) ,Adverse effect ,business ,media_common - Abstract
Patients receiving palliative care are at high risk of adverse effects from drugs. As these effects can be difficult to distinguish from the symptoms of the terminal illness, harm from medicines is often not recognised. Adverse effects can contribute to the burden of symptoms, at a time when good control of symptoms is paramount. Adding another drug to treat the adverse effects can compound the problem. Patients should be asked about their symptoms as they may not volunteer the information or recognise the link with their medicines. Reviewing their treatment may prompt a change in dose, drug or lead to some treatments being stopped. Refereed/Peer-reviewed
258. A realist review of programs fostering the resilience of healthcare students: What works, for whom and why?
- Author
-
Halimi SN, Rowett D, and Luetsch K
- Abstract
Background: Various programs aimed at fostering the resilience of students have been implemented into healthcare undergraduate and postgraduate educational courses and degree programs. Which of these increase their participants' resilience under which circumstances, for whom and why remains uncertain., Methods: A realist review of articles reporting program outcomes as measures of resilience through the use of via validated psychometric surveys was conducted to investigate which contexts favour the development of resilience of healthcare and health sciences students and which mechanisms have to be activated to achieve this outcome., Results: Thirteen Context-Mechanism-Outcome Configurations were synthesised from data presented in 43 articles. These were combined with theories explaining the theoretical and psychological frameworks underpinning programs to develop a program theory of how and why resilience fostering programs work. Contexts which favour the development of resilience were the use of validated psychological frameworks as program foundation, e.g. Cognitive Behavioural Therapy, mindfulness-based training. Expert facilitation, longitudinal integration into curricula, flexible and multi-modal design and delivery, and opportunities for students to apply and practice resilience-building strategies also created favourable contexts. Meeting students' or practitioners' needs activated mechanisms of trust, engagement and recognition of a program's value and real-world benefits. An increase in resilience was achieved by students developing reflective skills, metacognitive awareness and positive habits of mind., Conclusion: The program theory established via a realist review provides guidance on how the individual resilience of healthcare students can be fostered throughout their undergraduate, postgraduate degrees and early practice, potentially supporting them to flourish and remain long-term in their chosen professional roles., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
259. Exploration of 'micro' level factors that affect the involvement of clinical pharmacists in interprofessional ward rounds in hospitals: Through the lens of social cognitive theory.
- Author
-
Babu D, Rowett D, Kalisch Ellett L, Marotti S, Wisdom A, Lim R, and Harmon J
- Subjects
- Humans, Female, Male, South Australia, Pharmacists organization & administration, Pharmacy Service, Hospital organization & administration, Interprofessional Relations, Teaching Rounds, Professional Role, Attitude of Health Personnel
- Abstract
Background: Macro and meso level factors that influence the participation by clinical pharmacists in ward rounds include pharmacy management culture, commitment to ward rounds and adequate time for ward rounds being included in workload models. The 'micro' level factors that affect the involvement of clinical pharmacists in ward rounds have not been widely explored., Objective: Explore 'micro' level factors to gain insight into clinical pharmacists' participation in interprofessional ward rounds in inpatient settings through the lens of social cognitive theory., Method: A qualitative focused ethnographic study with five clinical pharmacists, four medical practitioners, one allied health professional and one nurse was conducted in three metropolitan hospitals in Southern Australia. Seven hours of semi-structured interview (n = 11) and 76-h of observations (n = 5) were conducted. A qualitative descriptive analysis was conducted (guided by Spradley) followed by reflexive thematic-analysis (according to Braun and Clarke's technique)., Results: Three micro level factors influencing clinical pharmacist participation in ward rounds are: (1) Cognitive mindset of clinical pharmacists, (2) Behavioural conduct of clinical pharmacists, and (3) Social rules of the ward. Clinical pharmacists that did not participate in ward round reconciled their moral distress by transferring information without clinical judgement or interpretation of the patient scenario to medical practitioners. Clinical pharmacists that did participate in ward rounds demonstrated credibility by making relevant recommendations with a holistic lens. This enabled clinical pharmacists to be perceived as trustworthy by medical practitioners. Positive experiences of participating in ward rounds contributed to their cognitive upward spiral of thoughts and emotions, fostering continued participation., Conclusion: Clinical pharmacists participate in ward rounds when they develop a positive mindset about ward round participation and perceive ward rounds as an enabler to the establishment of trusted professional relationships with medical practitioners. This trusted relationship creates an environment where the pharmacist develops confidence in making relevant recommendations., Competing Interests: Declaration of competing interest No competing interests., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
260. What is impacting clinical pharmacists' participation in an interprofessional ward round: a thematic analysis of a national survey.
- Author
-
Babu D, Marotti S, Rowett D, Lim R, Wisdom A, and Kalisch Ellett L
- Subjects
- Humans, Australia, Professional Role, Hospitals, Attitude of Health Personnel, Pharmacists, Interprofessional Relations
- Abstract
The ward round (WR) is an important opportunity for interprofessional interaction and communication enabling optimal patient care. Pharmacists' participation in the interprofessional WR can reduce adverse drug events and improve medication appropriateness and communication. WR participation by clinical pharmacists in Australia is currently limited. This study aims to explore what is impacting clinical pharmacists' participation in WRs in Australian hospitals. A self-administered, anonymous national survey of Australian clinical pharmacists was conducted. This study describes the outcomes from qualitative questions which were analyzed thematically in NVivo-2020 according to Braun and Clarke's techniques. Five themes were constructed: "Clinical pharmacy service structure", "Ward round structure", "Pharmacist's capabilities", "Culture" and "Value". A culture supportive of pharmacist's contribution with a consistent WR structure and flexible delivery of clinical pharmacy services enabled pharmacists' participation in WR. Being physically "absent" from the WR due to workload, workflow, and self-perception of the need for extensive clinical knowledge can limit opportunities for pharmacists to proactively contribute to medicines decision-making with physicians to improve patient care outcomes. Bidirectional communication between the interprofessional team and the pharmacist, where there is a co-construction of each individual's role in the WR facilitates consistent and inter-dependent collaborations for effective medication management.
- Published
- 2024
- Full Text
- View/download PDF
261. A realist synthesis of educational outreach visiting and integrated academic detailing to influence prescribing in ambulatory care: why relationships and dialogue matter.
- Author
-
Luetsch K, Wong G, and Rowett D
- Subjects
- Humans, Quality Improvement, Delivery of Health Care, Ambulatory Care
- Abstract
Background: Many quality improvement initiatives in healthcare employ educational outreach visits, integrating academic detailing to bridge evidence-practice gaps and accelerate knowledge translation. Replicability of their outcomes in different contexts varies, and what makes some visiting programmes more successful than others is unclear., Objective: We conducted a realist synthesis to develop theories of what makes educational outreach visiting integrating academic detailing work, for whom, under which circumstances and why, focusing on the clinician-visitor interaction when influencing prescribing of medicines in ambulatory care settings., Methods: The realist review was performed in accordance with RAMESES standards. An initial programme theory was generated, academic databases and grey literature were screened for documents with detail on contexts, intervention and outcomes. Using realist logic of analysis, data from 43 documents were synthesised in the generation of a refined programme theory, supported by additional theoretical frameworks of learning and communication., Results: Twenty-seven interdependent context-mechanism-outcome configurations explain how clinicians engage with educational outreach visits integrating academic detailing through programme design, what matters in programme design and the educational visitor-clinician interaction and how influence extends beyond the visit. They suggest that in addition to relevance, credibility and trustworthiness of a visit's contents, communication and clinical skills of educational visitors, the relationship between the educational visitor and clinician, built on a dialogue of learning from and sense-making with each other, creates conditions of critical thinking which are conducive to facilitating prescribing practice change when necessary., Conclusion: This realist synthesis elucidates that the quality of clinician-educational visitor interactions is pivotal to educational outreach visiting programmes. Building and sustaining relationships, and establishing an open dialogue are important; neglecting these undermines the impact of visits. Educational visitors can facilitate clinicians' reflection on practice and influence their prescribing. Clinicians value the discussion of individualised, tailored information and advice they can translate into their practice., Prospero Registration Number: CRD42021258199., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
262. Resilience and empathy in pharmacy interns: Insights from a three-year cohort study.
- Author
-
Halimi SN, Mirzaei A, Rowett D, Whitfield K, and Luetsch K
- Abstract
Background: Resilience and empathy are important attributes for healthcare professionals to navigate challenging work environments and providing patient-centred care. Knowledge about pharmacists' levels of resilience and empathy, particularly during the early stages of their careers, is limited., Objectives: To explore pharmacy interns' levels of resilience and empathy using the Connor-Davidson-Resilience-Scale-25 (CD-RISC-25) and the Kiersma-Chen-Empathy-Scale (KCES), examine potential associations with demographic characteristics and ascertain what challenges interns' resilience and which support mechanisms they identify., Methods: Hard copies of the surveys were distributed to three cohorts during face-to-face intern pharmacy workshops from 2020 to 2022. Additionally, a qualitative questionnaire explored interns' experiences while completing an accredited internship program during the COVID-19 pandemic. Data were analysed using descriptive and inferential statistics, open-ended questions were analysed through qualitative and quantitative content analysis., Results: Among 134 completed surveys, most respondents were female, aged 18-22, and worked in hospitals. The CD-RISC-25 mean score was 66.6 (SD 11.7) and the KCES mean was 84.3 (SD 9.23) indicative of intermediate levels of resilience and empathy. Resilience and empathy scores did not significantly differ between the three cohorts ( p-value > 0.05), and both were not consistently correlated with each other ( p-value > 0.05). No significant associations were found between demographic characteristics and resilience scores. However, age and pre-internship employment history showed a statistically significant association with empathy scores ( p-value < 0.05), with younger age groups and those who worked part-time during undergraduate studies demonstrating higher levels of empathy. Challenges undermining interns' resilience included the COVID-19 pandemic, internship requirements, and feelings of inadequacy and inexperience., Conclusions: This study showed that resilience and empathy scores among interns were at what can be regarded as intermediate levels, largely unaffected by the COVID-19 pandemic or cohort demographics. It highlights professional aspects and strategies which are professionally sustaining and may assist interns in navigating challenges to their resilience and empathy., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
263. Clinical pharmacists' participation in ward rounds in hospitals: responses from a national survey.
- Author
-
Babu D, Rowett D, Lim R, Marotti S, Wisdom A, and Ellett LK
- Subjects
- Humans, Adolescent, Adult, Pharmacists, Australia, Hospitals, Surveys and Questionnaires, Attitude of Health Personnel, Professional Role, Drug-Related Side Effects and Adverse Reactions, Pharmacy Service, Hospital
- Abstract
Objectives: The inclusion of clinical pharmacists in ward rounds (WRs) can reduce adverse drug events, improve communication and enable collaborative decision-making. The aim of this study is to investigate the level of and factors that influence WR participation by clinical pharmacists in Australia., Methods: An online administered, anonymous survey of clinical pharmacists in Australia was conducted. The survey was open to pharmacists aged ≥18 years, who had worked in an Australian hospital in a clinical role in the previous two weeks. It was distributed via The Society of Hospital Pharmacists of Australia and on pharmacist-specific social media threads. Survey questions related to the extent of WR participation and factors that influence WR participation. Cross-tabulation analysis was conducted to determine whether there was an association between WR participation and factors that influence WR participation., Key Findings: Ninety-nine responses were included. The level of WR participation by clinical pharmacists in Australian hospitals was low, with only 26/67 (39%) pharmacists who had a WR in their clinical unit actually attending the WR in the previous 2 weeks. Factors that influenced WR participation included having recognition of the role of the clinical pharmacist within the WR team, support from pharmacy management and the broader interprofessional team, and having adequate time and expectation from pharmacy management and colleagues to participate in WRs., Conclusions: This study highlights the need for ongoing interventions such as restructuring workflows and increasing the awareness of the role of a clinical pharmacist in WR to increase participation of pharmacists in this interprofessional activity., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society.)
- Published
- 2023
- Full Text
- View/download PDF
264. Pharmacists as patient advocates: A series of case studies illustrating the impacts of a regular pharmacist service in residential aged care (nursing homes).
- Author
-
Lim R, Bilton R, Dorj G, Bereznicki L, Rowett D, Ho JN, Freeman A, and Roughead EE
- Abstract
Background: Medicine-related problems are common in older people living in residential aged care facilities (RACFs). Recognising the significant medicine-related problems, the Australian government has announced a $345 million funding package to employ on-site pharmacists in RACFs starting in 2023. The new on-site pharmacists are to provide a range of clinical services to reduce medicine-related adverse events, promote quality use of medicines, and improve clinical governance and education. Underpinning these services, the authors argue that pharmacists play the critical role as resident advocates., Objective: This study aims to demonstrate how pharmacists can enhance their advocacy responsibility within and beyond the clinical environment to not only reduce medicine-related adverse events but also improve residents' overall health and quality of life., Methods: This study uses a case series methodology to demonstrate pharmacists' diverse roles in advocating for residents and their families. The case studies were based on participants enrolled in the Reducing Medicine-Induced Deterioration and Adverse Reactions (ReMInDAR) trial, a randomised controlled trial testing the effects of a regular pharmacist service across the Australian RACFs., Results: Pharmacists' advocacy ranged from persistence in follow-up with a resident's general practitioner (GP) to ensure the GP was aware that a patient was experiencing bleeding and bruising while on an anticoagulant, to advocating for a new bed for a resident with peripheral oedema who had been sleeping in his chair due to fear of falling out of his current bed., Conclusions: Our trial focussed on pharmacists serving as the residents' advocate to improve their overall health and quality of life, rather than just addressing a list of medicine-related problems. The pharmacist model used in the ReMInDAR trial supports pharmacists to work to their full scope of practice, helps guide the Australian government's new on-site pharmacist program, and serves as an exemplar pharmacist in aged care model internationally., Competing Interests: RB was employed as the ReMInDAR partnership engagement and trial manager to oversee the operations management for the trial. All other authors declare that they have no competing interests., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
265. How early career pharmacists understand resilience - A qualitative study of experiences, challenges and strategies.
- Author
-
Halimi SN, Rowett D, Whitfield K, and Luetsch K
- Subjects
- Humans, Pandemics, Health Personnel, Qualitative Research, Professional Role, Pharmacists, COVID-19
- Abstract
Introduction: Resilience assists healthcare professionals in negotiating challenges, remaining positive when experiencing adversity, and in constructively dealing with difficult work situations and environments. There is increasing research about how early career healthcare professionals, understand and maintain resilience but little is known about support early career pharmacists may need and value., Aims: To explore early career pharmacists' understanding of resilience, their strategies to enhance and maintain resilience as healthcare professionals and to identify resilience-fostering programmes they perceive could be implemented to support them., Methods: Three focus groups and 12 semi-structured interviews with a total of 15 hospital pharmacists and 10 community pharmacists (both less than 3 years post-registration) were conducted. An inductive thematic analysis of transcripts was performed to identify main themes and subthemes., Results: Pharmacists understood resilience as the capability to adapt to and learn from challenges and setbacks, which they can build through experience and exposure. Resilience in the workplace was challenged by their working environment and workload, which could lead to ego depletion, the transition from intern to registered pharmacist and working during the COVID-19 pandemic, which both added pressure and uncertainty to their role. Professional resilience was supported on individual, social and organisational levels and through self-care strategies. Pharmacists perceived mentorship and sharing experiences, experiential placements and constructive but challenging role play as potentially beneficial in building resilience during undergraduate studies and internship., Discussion: Pharmacists defined resilience constructively and identified challenges testing but also strategies supporting their resilience in the workplace. Workplaces can support pharmacists by monitoring workload and workplace relationships, creating opportunities for peer and mentor support and by allowing pharmacists to implement their personal, individualised resilience maintaining strategies. Early career pharmacists' experiences and insights would be valuable when considering the design and implementation of resilience-fostering programmes., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
266. Vaccination Rates, Perceptions, and Information Sources Used by People With Inflammatory Arthritis.
- Author
-
Lyon A, Quinlivan A, Lester S, Barrett C, Whittle SL, Rowett D, Black R, Sinnathurai P, March L, Buchbinder R, and Hill CL
- Abstract
Objective: To determine vaccination rates, perceptions, and information sources in people with inflammatory arthritis., Methods: Participants enrolled in the Australian Rheumatology Association Database were invited to participate in an online questionnaire, conducted in January 2020, prior to the COVID-19 pandemic. Included questions were about vaccination history, modified World Health Organization Vaccination Hesitancy Scale, views of the information sources consulted, the Beliefs About Medicines Questionnaire, education, and the Single-Item Health Literacy Screener., Results: Response rate was 994 of 1498 (66%). The median age of participants was 62 years, with 67% female. Self-reported adherence was 83% for the influenza vaccine. Participants generally expressed positive vaccination views, particularly regarding safety, efficacy, and access. However, only 43% knew which vaccines were recommended for them. Vaccine hesitancy was primarily attributable to uncertainty and a perceived lack of information about which vaccines were recommended. Participants consulted multiple vaccination information sources (median 3, interquartile range 2-7). General practitioners (89%) and rheumatologists (76%) were the most frequently used information sources and were most likely to yield positive views. Negative views of vaccination were most often from internet chatrooms, social media, and mainstream media. Factors of younger age, male gender, and having more concerns about the harms and overuse of medicines in general were associated with lower adherence and greater uncertainty about vaccinations, whereas education and self-reported literacy were not., Conclusion: Participants with inflammatory arthritis generally held positive views about vaccination, although there was considerable uncertainty as to which vaccinations were recommended for them. This study highlights the need for improved consumer information about vaccination recommendations for people with inflammatory arthritis., (© 2023 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
- Published
- 2023
- Full Text
- View/download PDF
267. Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions.
- Author
-
Khoo T, Sidhu N, Marine F, Lester S, Quinlivan A, Rowett D, Buchbinder R, and Hill CL
- Abstract
Background: Biologic and targeted synthetic disease modifying agents (b/tsDMARDs) have broadened the treatment landscape for autoimmune diseases particularly in patients refractory to conventional DMARDs. More recently, the introduction of biosimilars has reduced the price of bDMARDs, potentially improving accessibility. Though efficacy and safety have been described, patient attitudes to b/tsDMARDs are not well-understood. We aim to investigate patients' beliefs about biologic and biosimilar therapy, and the factors influencing their perceptions., Methods: Patient consumer groups (Arthritis Australia, Crohn's and Colitis Australia) assisted in advertising an online questionnaire for people with a self-reported diagnosis of inflammatory arthritis (IA) or inflammatory bowel disease (IBD). The questionnaire incorporated the Belief about Medicines Questionnaire (BMQ) and the single-item literacy screener (SILS). Sources and favourability of biologic/biosimilar information were analysed, using the chi-square and a non-parametric trend test for unordered and ordered categorical variables respectively, comparing respondents with IA and IBD., Results: Eight hundred and thirty eight people (686-IA, 144-IBD, 8 both) responded. 658 (79%) used b/tsDMARDs. The BMQ demonstrated high necessity belief (median 4.2) with moderate concerns (median 2.8) about biologics. 95% of respondents obtained medication information from specialists though most used multiple sources (median 4). The most positive resources were specialists and specialist nurses. 73/141 (52%) respondents with IBD obtained information from specialist nurses compared with 202/685 (29%) with IA (p = 0.012). Respondents with limited reading ability on SILS were more likely to discuss information with a general practitioner or pharmacist. Younger respondents and those with higher BMQ concern scores more frequently consulted less reliable sources (e.g. social media). 502 respondents (60%) answered the biosimilar questions. Only 23 (4.6%) reported currently using a biosimilar and 336 (66.9%) were unsure if biosimilars were available in Australia. Specialist recommendation was the most frequent factor that would influence a patient to change from originator to biosimilar (352/495, 71.1%)., Conclusions: There is a high level of trust in specialists' recommendations about b/tsDMARDs, although most people also utilise additional information sources. Contextual factors influencing resource selection include age, reading ability and degree of concern about medicines. People with IA and IBD have similar attitudes though those with IBD more frequently access specialist nurse advice., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
268. Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars.
- Author
-
Quinlivan A, Lester S, Barrett C, Whittle S, Rowett D, Black R, Chand V, Marine F, March L, Sinnathurai P, Buchbinder R, and Hill C
- Abstract
Objectives: To investigate the knowledge and beliefs of Australian patients with inflammatory arthritis regarding biologic/targeted synthetic DMARDs (b/tsDMARDs) and biosimilars and their sources of information., Methods: Participants enrolled in the Australian Rheumatology Association Database (ARAD) with RA, PsA and axial SpA were sent an online survey. They were asked about information sources for b/tsDMARDs and how positive or negative this information was. The Beliefs about Medicine Questionnaire (BMQ) was used to measure beliefs about b/tsDMARDs with scores ranging from 1 (strongly disagree) to 5 (strongly agree). Participants were asked about their knowledge of biosimilars and willingness to switch to biosimilar., Results: There was a response rate of 66% (994/1498; 67% female, median age 62 years). Participants currently taking b/tsDMARDs ( n = 794) had a high b/tsDMARD-specific BMQ 'necessity' score {median 4.2 [interquartile range (IQR) 3.6-4.8]}, with a lower specific 'concerns' score [median 2.4 (IQR 2.0- 3.0)]. Participants consulted multiple information sources [median 3 (IQR 2-5)]. Positive sources were rheumatologists and educational websites and negative were chat rooms and social media. Only 18% were familiar with biosimilars, with half knowing of availability in Australia. Following a short paragraph describing biosimilars, 75% (744) of participants indicated they would consider switching if recommended by their rheumatologist, with nearly half identifying safety and efficacy of biosimilars as an important concern., Conclusion: Australian patients have positive attitudes towards b/tsDMARDs overall, although little knowledge of biosimilars specifically. They have a high degree of trust in their rheumatologist regarding treatment decisions, even if they are unfamiliar with the medication recommended., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2022
- Full Text
- View/download PDF
269. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
- Author
-
Lalor AF, Brooker JE, Rozbroj T, Whittle SL, Hill CL, Rowett D, Buchbinder R, and O'Connor DA
- Subjects
- Humans, Qualitative Research, Rheumatologists, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy, Biosimilar Pharmaceuticals therapeutic use
- Abstract
Understanding factors that influence prescribing of disease-modifying anti-rheumatic drugs (DMARDs) will inform strategies to optimise care of people with inflammatory arthritis. We performed a systematic review and thematic synthesis of qualitative studies to explore these factors. Inclusion criteria were: use of qualitative or mixed methods; rheumatologist, nurse or pharmacist perspectives; prescription of any DMARD (conventional [cs], targeted synthetic [ts], biologic [b], biosimilars) and/or glucocorticoids; in any healthcare setting in any country. MEDLINE, Embase and EBSCOhost CINAHL Plus were searched from inception to 15 June 2021. Pairs of review authors independently identified studies for inclusion, assessed methodological quality using the Critical Appraisal Skills Programme checklist, and extracted and thematically synthesised data. Confidence in synthesis themes was evaluated using the GRADE Confidence in Evidence from Reviews of Qualitative research (CERQual) approach. We included 15 studies involving 716 clinicians (683 rheumatologists, 27 nurses, 6 pharmacists) across 10 countries, all focusing on management of patients with rheumatoid arthritis (RA). Six themes were identified: Rheumatologist prescribing is influenced by patients' characteristics, preferences, symptoms and negative responses to medication; Rheumatologist knowledge, experience, habits and subjective judgements are strong drivers of prescribing behaviour; High demands on consultation time impede shared decision-making; Costs and complexity of medication funding arrangements limit prescribing options; Clinicians recognise the importance of providing patient education about medication options; and Clinicians value colleagues' opinions and support to inform prescribing decisions. The majority of themes were graded as moderate confidence (n = 4), reflecting they are likely to reasonably represent the factors influencing prescribing of DMARDs to people with RA. Quality improvement strategies that address these factors are likely to support best practice pharmacologic management of RA and may be potentially applicable to other types of inflammatory arthritis. High demand on consultation time and complexity of medication funding arrangements are system factors that may or may not be amenable to change. Easily accessible living national guidelines which include lay summaries and treatment algorithms to support prescribing decisions may address some of the themes., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
270. Realist research to inform pharmacy practice and policy.
- Author
-
Luetsch K, Maidment I, Twigg M, and Rowett D
- Subjects
- Delivery of Health Care, Humans, Policy, Research Design, Pharmaceutical Services, Pharmacies, Pharmacy
- Abstract
Theory-driven implementation and evaluation of pharmacy services can enhance their contribution to overall healthcare. As complex interventions most pharmacy practice programmes and services will be adopted and modified during their implementation into various healthcare contexts and systems. Realist approaches to theory-driven evaluation consider these variations in programmes, interventions and the contexts of their implementation and establish theories on how they work best, for whom and why. This paper illustrates the practical application of the realist philosophy of science to pharmacy practice relevant areas of healthcare using two case studies, a realist synthesis of existing literature on medication reviews and a realist review and evaluation related to medicines management. Applying realist logic establishes causative explanations of what could be essential factors in the success of programmes, enabling policy makers in their decision-making and pharmacy practice researchers as well as practitioners in optimising service design., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
271. Patient-Centered Educational Resources for Atrial Fibrillation.
- Author
-
Gallagher C, Rowett D, Nyfort-Hansen K, Simmons S, Brooks AG, Moss JR, Middeldorp ME, Hendriks JM, Jones T, Mahajan R, Lau DH, and Sanders P
- Subjects
- Anti-Arrhythmia Agents therapeutic use, Anticoagulants therapeutic use, Disease Management, Health Literacy, House Calls, Humans, Patient Medication Knowledge, Patient-Centered Care, Stroke etiology, Stroke prevention & control, Atrial Fibrillation therapy, Pamphlets, Patient Education as Topic methods, Self-Management, Teaching Materials
- Abstract
Education has long been recognized as an important component of chronic condition management. Whereas education has been evaluated in atrial fibrillation (AF) populations as part of multifaceted interventions, it has never been tested as a single entity. The aim of this review is to describe the rationale for and role of education as part of comprehensive AF management. The development and use of educational material as part of the intervention of a randomized controlled trial, the HELP-AF (Home-Based Education and Learning Program in AF) study, will be described. This study was designed to determine the impact of a home-based structured educational program on outcomes in individuals with AF. An educational resource was developed to facilitate delivery of 4 key messages targeted at empowering individuals to self-manage their condition. The key messages focused on strategies for managing future AF episodes, the role of pharmacotherapy in the treatment of AF, the appropriate use of medicines to manage stroke risk and the role of cardiovascular risk factor management in AF. To support structured educational visiting, an educational booklet titled Living Well With Atrial Fibrillation (AF) was developed by a multidisciplinary team and was further refined following input from expert clinicians and patient interviews. Using a structured educational visiting approach, education was delivered by trained clinicians within the patient's home., (Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
272. Academic detailing as a method of continuing medical education.
- Author
-
Dyrkorn R, Langaas HC, Giverhaug T, Espnes KA, Rowett D, and Spigset O
- Abstract
Introduction: Academic detailing is an interactive educational outreach to prescribers to present unbiased, non-commercial, evidence-based information, mostly about medications, with the goal of improving patient care. Academic detailing in Norway is an approach for providing continuing medical education to general practitioners (GPs). The basis of academic detailing is a one-to-one discussion between a trained health professional (the academic detailer) and the GP at the GP's workplace., Method: Our first campaign was named "Better use of non-steroidal anti-inflammatory drugs (NSAIDs) " , which aim was to reduce the use of diclofenac due to the risk of serious cardiovascular adverse events. At the same time we advised the GPs to use naproxen as the drug of choice if an NSAID was needed. We did a one-to-one intervention in two cities, where a trained academic detailer met the GP during office hours. A total of 247 GPs were invited to participate and 213 visits (86%) were completed. This article reviews the theoretical framework underlying the method and describes the development and implementation of academic detailing to GPs in Norway., Results: More than 90% the participating GPs considered academic detailing a suitable method for providing up-to-date evidence-based, manufacturer-independent information, and nearly all would most likely or probably welcome another visit. After the intervention there was a reduction of diclofenac prescribing of 16% and 18%, respectively, in the two cities., Conclusion: We consider that academic detailing is a suitable method to bring the best available evidence to the point at which care is delivered, to achieve the best for the patients. According to the Norwegian GPs' evaluation, it is a key supplement to other methods of continuing medical education. To have maximum impact, it is important that academic detailing is practiced according to the consensus that has evolved in the USA and Australia., Competing Interests: Mr Harald Christian Langaas reports grants from Norwegian Directorate of Health, during the conduct of the study. The authors report no other conflicts of interest in this work. Box 1The steps of academic detailing1,2,13● Focusing programs on specific categories of physicians as well as on their opinion leader.● Investigating baseline knowledge and motivations for current activity.● Defining clear educational and behavioral objectives.● Establishing credibility through a respected organizational identity, referencing authoritative and unbiased sources of information, and presenting both sides of controversial issues.● Stimulating active participation by physicians in educational interactions.● Using concise graphic educational materials that highlight and repeat essential messages.● Providing positive reinforcement of improved practices at follow-up visits.
- Published
- 2019
- Full Text
- View/download PDF
273. Home-Based Education and Learning Program for Atrial Fibrillation: Rationale and Design of the HELP-AF Study.
- Author
-
Hendriks JM, Brooks AG, Rowett D, Moss JR, Gallagher C, Nyfort-Hansen K, Simmons S, Middeldorp ME, Jones T, Thomas G, Lau DH, and Sanders P
- Subjects
- Humans, Multicenter Studies as Topic, Patient Admission, Prospective Studies, Quality of Life, Randomized Controlled Trials as Topic, Atrial Fibrillation therapy, Emergency Service, Hospital, Home Care Services, Hospital-Based, Patient Education as Topic
- Abstract
Background: Atrial fibrillation (AF) is a growing global epidemic, with its prevalence expected to significantly rise over coming decades. AF poses a substantial burden on health care systems, largely due to hospitalizations. Home-based clinical characterization has demonstrated improved outcomes in cardiac populations, but its impact on AF remains poorly defined. To test this hypothesis in AF, we developed the Home-Based Education and Learning Program for Patients With Atrial Fibrillation (HELP-AF) study., Methods: The HELP-AF study is a prospective multicentre randomized controlled trial that will recruit 620 patients presenting to hospital emergency departments (EDs) with symptomatic AF (ANZCTR Registration: ACTRN12611000607976). Patients will be randomized to either the HELP-AF intervention or usual care. The intervention consists of 2 home visits by a nurse or pharmacist trained in the structured educational visiting (SEV) method. Patients in the control group will receive usual discharge follow-up care., Results: The primary endpoints are total unplanned hospital admissions and quality of life. Secondary endpoints include AF symptom severity and burden score; time to first hospital admission; total unplanned days in hospital; total AF-related hospital admissions (including atrial flutter); total cardiac and noncardiac hospital admissions; total AF- or atrial flutter-related; cardiac- and noncardiac-related ED presentations; and all-cause mortality. An economic evaluation will also be performed. Clinical endpoints will be adjudicated by independent blinded assessors. Follow-up will be at 24 months., Conclusions: This study will assess the efficacy of a home-based structured patient-centred educational intervention in patients with AF., (Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
274. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
- Author
-
Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, and Currow DC
- Subjects
- Administration, Oral, Aged, Australia, Double-Blind Method, Female, Geriatric Assessment, Humans, Male, Placebos, Treatment Outcome, Antipsychotic Agents administration & dosage, Delirium drug therapy, Haloperidol administration & dosage, Palliative Care methods, Risperidone administration & dosage
- Abstract
Importance: Antipsychotics are widely used for distressing symptoms of delirium, but efficacy has not been established in placebo-controlled trials in palliative care., Objective: To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care., Design, Setting, and Participants: A double-blind, parallel-arm, dose-titrated randomized clinical trial was conducted at 11 Australian inpatient hospice or hospital palliative care services between August 13, 2008, and April 2, 2014, among participants with life-limiting illness, delirium, and a delirium symptoms score (sum of Nursing Delirium Screening Scale behavioral, communication, and perceptual items) of 1 or more., Interventions: Age-adjusted titrated doses of oral risperidone, haloperidol, or placebo solution were administered every 12 hours for 72 hours, based on symptoms of delirium. Patients also received supportive care, individualized treatment of delirium precipitants, and subcutaneous midazolam hydrochloride as required for severe distress or safety., Main Outcome and Measures: Improvement in mean group difference of delirium symptom score (severity range, 0-6) between baseline and day 3. Five a priori secondary outcomes: delirium severity, midazolam use, extrapyramidal effects, sedation, and survival., Results: Two hundred forty-seven participants (mean [SD] age, 74.9 [9.8] years; 85 women [34.4%]; 218 with cancer [88.3%]) were included in intention-to-treat analysis (82 receiving risperidone, 81 receiving haloperidol, and 84 receiving placebo). In the primary intention-to-treat analysis, participants in the risperidone arm had delirium symptom scores that were significantly higher than those among participants in the placebo arm (on average 0.48 Units higher; 95% CI, 0.09-0.86; P = .02) at study end. Similarly, for those in the haloperidol arm, delirium symptom scores were on average 0.24 Units higher (95% CI, 0.06-0.42; P = .009) than in the placebo arm. Compared with placebo, patients in both active arms had more extrapyramidal effects (risperidone, 0.73; 95% CI, 0.09-1.37; P = .03; and haloperidol, 0.79; 95% CI, 0.17-1.41; P = .01). Participants in the placebo group had better overall survival than those receiving haloperidol (hazard ratio, 1.73; 95% CI, 1.20-2.50; P = .003), but this was not significant for placebo vs risperidone (hazard ratio, 1.29; 95% CI, 0.91-1.84; P = .14)., Conclusions and Relevance: In patients receiving palliative care, individualized management of delirium precipitants and supportive strategies result in lower scores and shorter duration of target distressing delirium symptoms than when risperidone or haloperidol are added., Trial Registration: anzctr.org.au Identifier: ACTRN12607000562471.
- Published
- 2017
- Full Text
- View/download PDF
275. Interprofessional communication training: benefits to practicing pharmacists.
- Author
-
Luetsch K and Rowett D
- Subjects
- Humans, Patient Care Team, Qualitative Research, Attitude of Health Personnel, Communication, Education, Pharmacy, Continuing, Interprofessional Relations, Pharmacists psychology
- Abstract
Background: Interprofessional communication skills are important for pharmacists to build collaborative relationships with other health professionals, integrate into healthcare teams, maximise their effectiveness in patient care in addressing complex care needs and meet the demands of health care reforms., Objective: This qualitative study explores clinical pharmacists' experiences and reflections after completing a learning and practice module which introduced them to a framework for successful interprofessional communication., Setting: The postgraduate clinical pharmacy program at The University of Queensland and the clinical pharmacy practice environments of forty-eight hospital and seven community based pharmacists., Method: A learning and practice module outlining a framework for successful interprofessional communication was designed and integrated into a postgraduate clinical pharmacy program. Enrolled pharmacists applied newly learnt communication skills in pro-actively initiated, clinical discussions with a health professional in their practice environment. They provided written reflections on their experiences which were analysed using thematic analysis., Main Outcome: Pharmacists' perceptions of the impact of applying the communication framework during their interaction with a health professional in their practice setting., Results: Themes which emerged from reflections described pharmacists' confidence and capabilities to successfully conduct a clinical discussion with a health professional after initial apprehension and nervousness about the scheduled interaction. The application of the communication framework enhanced their perception of their professional identity, credibility and ability to build a collaborative working relationship with other health professionals., Conclusions: Pharmacists perceived that a learning and practice module for successful interprofessional practice integrated into a postgraduate clinical pharmacy program enhanced their interprofessional communication skills. The development of pro-active, interprofessional communication skills has the potential to increase interprofessional collaboration and pharmacists' personal role satisfaction. Pharmacists also observed it added value to their professional contribution in health care teams when addressing the demands of increasingly complex health care needs and reforms.
- Published
- 2015
- Full Text
- View/download PDF
276. Chronic refractory dyspnoea--evidence based management.
- Author
-
Wiseman R, Rowett D, Allcroft P, Abernethy A, and Currow DC
- Subjects
- Benzodiazepines therapeutic use, Chronic Disease, Dyspnea drug therapy, Heart Failure complications, Humans, Lung Diseases, Interstitial complications, Morphine therapeutic use, Neurodegenerative Diseases complications, Oxygen Inhalation Therapy, Pulmonary Disease, Chronic Obstructive complications, Quality of Life, Walking, Dyspnea etiology, Dyspnea therapy
- Abstract
Background: Chronic refractory dyspnoea is defined as breathlessness daily for 3 months at rest or on minimal exertion where contributing causes have been treated maximally. Prevalent aetiologies include chronic obstructive pulmonary disease, heart failure, advanced cancer and interstitial lung diseases., Objective: To distil from the peer reviewed literature (literature search and guidelines) evidence that can guide the safe, symptomatic management of chronic refractory dyspnoea., Discussion: Dyspnoea is mostly multifactorial. Each reversible cause should be managed (Level 4 evidence). Non-pharmacological interventions include walking aids, breathing training and, in chronic obstructive pulmonary disease, pulmonary rehabilitation (Level 1 evidence). Regular, low dose, sustained release oral morphine (Level 1 evidence) titrated to effect (with regular aperients) is effective and safe. Oxygen therapy for patients who are not hypoxaemic is no more effective than medical air. If a therapeutic trial is indicated, any symptomatic benefit is likely within the first 72 hours.
- Published
- 2013
277. Osteoporosis - pharmacological prevention and management in older people.
- Author
-
Bell JS, Blacker N, Edwards S, Frank O, Alderman CP, Karan L, Husband A, and Rowett D
- Subjects
- Aged, Aged, 80 and over, Bone Density drug effects, Female, Humans, Male, Osteoporosis prevention & control, Risk Factors, Bone Density Conservation Agents therapeutic use, Calcium therapeutic use, Diphosphonates therapeutic use, Fractures, Bone prevention & control, Osteoporosis drug therapy, Vitamin D therapeutic use
- Abstract
Background: Osteoporosis remains undertreated in Australian primary care, with as few as 30% of postmenopausal women with a fracture and 10% of men with osteoporosis receiving pharmacological treatment., Objective: This article presents an overview of the pharmacological management of osteoporosis in older people in the general practice setting., Discussion: Lifestyle factors and ensuring adequate calcium and vitamin D intake are important in preventing and treating osteoporosis. Pharmacological treatments are recommended for patients with a minimal trauma fracture, for those aged 70 years or over with a T-score of -3.0 or lower, or for those who are currently taking prolonged high dose corticosteroids and who have a T-score of -1.5 or lower. Bisphosphonates are recommended as first line therapy for established postmenopausal osteoporosis. Medicine selection is guided by patient gender, menopausal status, medical and fracture history, patient preference and eligibility for government subsidy.
- Published
- 2012
278. Anticholinergic and sedative medicines - prescribing considerations for people with dementia.
- Author
-
Bell JS, Mezrani C, Blacker N, LeBlanc T, Frank O, Alderman CP, Rossi S, Rowett D, and Shute R
- Subjects
- Antidepressive Agents adverse effects, Antipsychotic Agents adverse effects, Histamine Antagonists adverse effects, Humans, Cholinergic Antagonists adverse effects, Cholinesterase Inhibitors adverse effects, Cognition Disorders chemically induced, Dementia metabolism, Hypnotics and Sedatives adverse effects
- Abstract
Background: Older people with dementia may be particularly susceptible to cognitive impairment associated with anticholinergic and sedative medicines. This impairment may be misattributed to the disease process itself., Objective: This review examines clinical considerations associated with using anticholinergic and sedative medicines in people with dementia or incipient cognitive impairment. It highlights issues associated with concomitant use of cholinesterase inhibitors and anticholinergic medicines, and pharmacotherapy of conditions that commonly occur in people with dementia., Discussion: Use of medicines with anticholinergic or sedative properties may result in adverse events by increasing the overall anticholinergic or sedative load. Patients may benefit from clinicians reviewing the anticholinergic load of the current medicine regimen before the initiation of cholinesterase inhibitors or memantine. Reducing the number and dose of anticholinergic and sedative medicines may improve cognitive function and reduce the likelihood of adverse events.
- Published
- 2012
279. Cancer pain--progress and ongoing issues in Australia.
- Author
-
Currow DC and Rowett DS
- Subjects
- Analgesics, Opioid supply & distribution, Analgesics, Opioid therapeutic use, Australia, Humans, Longitudinal Studies, National Health Programs economics, National Health Programs statistics & numerical data, Pain drug therapy, Neoplasms complications, Pain etiology, Pain Management
- Published
- 2009
280. Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.
- Author
-
Jackowski L, Stocks N, and Rowett D
- Subjects
- Clopidogrel, Drug Therapy, Combination, Humans, Ticlopidine therapeutic use, Aspirin therapeutic use, Platelet Aggregation Inhibitors therapeutic use, Thrombosis complications, Thrombosis prevention & control, Ticlopidine analogs & derivatives
- Abstract
Clopidogrel and aspirin both inhibit platelet aggregation, but have differing mechanisms of action that are additive in terms of antithrombotic function. The additive antithrombotic effect of aspirin and clopidogrel combination therapy provides additional clinical benefit compared to monotherapy in some circumstances, but the risk of major bleeding with combination therapy is greater than with either agent alone.
- Published
- 2008
281. Adults with diabetes - pharmacological management of hypertension.
- Author
-
Jackowski L, Crockett J, and Rowett D
- Subjects
- Adrenergic beta-Antagonists, Adult, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents classification, Calcium Channel Blockers, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Humans, Hypertension complications, Life Style, Risk, Antihypertensive Agents therapeutic use, Diabetes Complications, Hypertension drug therapy
- Abstract
Cardiovascular and renal disease are leading causes of morbidity and mortality in patients with diabetes. Hypertension is an independent risk factor for both macrovascular (stroke, myocardial infarct, peripheral vascular disease) and microvascular (nephropathy, neuropathy, retinopathy) complications, and is a common co-existing condition in diabetes.
- Published
- 2008
282. Lipid lowering therapy for adults with diabetes.
- Author
-
Jackowski L, Crockett J, and Rowett D
- Subjects
- Adult, Australia epidemiology, Cardiovascular Diseases etiology, Diabetes Mellitus epidemiology, Humans, Hyperglycemia complications, Hyperglycemia epidemiology, Hyperlipidemias complications, Life Style, Practice Guidelines as Topic, Diabetes Mellitus drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hyperglycemia drug therapy, Hyperlipidemias drug therapy, Hypolipidemic Agents therapeutic use
- Abstract
The number of adults in Australia with diabetes has trebled over the past 2 decades. Diabetes confers an increased risk of cardiovascular disease (CVD) and CVD is the leading cause of morbidity and mortality in patients with diabetes. Hyperlipidaemia occurs commonly in people with diabetes and is an independent CVD risk factor.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.